Belapectin
| Clinical data | |
|---|---|
| Other names |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| UNII | |
Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics that is in clinical trials for the treatment of non-alcoholic steatohepatitis.[1][2][3][4]
References
[edit]- ^ Mireku, Akosua (26 June 2023). "NASH drugs race to cross the finish line". Pharmaceutical Technology. Retrieved 21 October 2023.
- ^ Al Attar, Atef; Antaramian, Ani; Noureddin, Mazen (3 April 2021). "Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis". Expert Review of Clinical Pharmacology. 14 (4): 457–464. doi:10.1080/17512433.2021.1894127.
- ^ Slack, R.J.; Mills, R.; Mackinnon, A.C. (January 2021). "The therapeutic potential of galectin-3 inhibition in fibrotic disease". The International Journal of Biochemistry & Cell Biology. 130: 105881. doi:10.1016/j.biocel.2020.105881.
- ^ Tapper, Elliot B.; Ufere, Nneka N.; Huang, Daniel Q.; Loomba, Rohit (May 2022). "Review article: current and emerging therapies for the management of cirrhosis and its complications". Alimentary Pharmacology & Therapeutics. 55 (9): 1099–1115. doi:10.1111/apt.16831. ISSN 0269-2813.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |